Development of ligand-targeted liposomes for cancer therapy

被引:123
作者
Noble, CO
Kirpotin, DB
Hayes, ME
Mamot, C
Hong, K
Park, JW
Benz, CC
Marks, JD
Drummond, DC
机构
[1] Hermes Biosci Inc, San Francisco, CA 94080 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Buck Inst Age Res, Novato, CA 94945 USA
关键词
immunoliposomes; ligand-directed therapeutics; ligand-targeted liposomes; receptor-mediated endocytosis; receptor-targeted liposomes; targeted drug delivery;
D O I
10.1517/14728222.8.4.335
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The continued evolution of targeted liposomal therapeutics has resulted in new agents with remarkable antitumour efficacy and relatively mild toxicity profiles. A careful selection of the ligand is necessary to reduce immunogenicity, retain extended circulation lifetimes, target tumour-specific cell surface epitopes, and induce internalisation and subsequent release of the therapeutic substance from the liposome. Methods for assembling targeted liposomes, including a novel micellar insertion technology, for incorporation of targeting molecules that efficiently transforms a non-targeted liposomal therapeutic to a targeted one, greatly assist the translation of targeted liposome technology into the clinic. Targeting strategies with liposomes directed at solid tumours and vascular targets are discussed. The authors believe the development of ligand-targeted liposomes is now in the advanced stage and offers unique and important advantages among other targeted therapies. Anti-HER2 immunoliposomal doxorubicin is awaiting Phase I clinical trials, the results of which should provide new insights into the promise of ligand-targeted liposomal therapies.
引用
收藏
页码:335 / 353
页数:19
相关论文
共 137 条
[1]  
AHMAD I, 1993, CANCER RES, V53, P1484
[2]   PHARMACOKINETICS OF LONG-CIRCULATING LIPOSOMES [J].
ALLEN, TM ;
HANSEN, CB ;
DEMENEZES, DEL .
ADVANCED DRUG DELIVERY REVIEWS, 1995, 16 (2-3) :267-284
[3]   Ligand-targeted therapeutics in anticancer therapy [J].
Allen, TM .
NATURE REVIEWS CANCER, 2002, 2 (10) :750-763
[4]   Liposomal drug formulations - Rationale for development and what we can expect for the future [J].
Allen, TM .
DRUGS, 1998, 56 (05) :747-756
[5]   A NEW STRATEGY FOR ATTACHMENT OF ANTIBODIES TO STERICALLY STABILIZED LIPOSOMES RESULTING IN EFFICIENT TARGETING TO CANCER-CELLS [J].
ALLEN, TM ;
BRANDEIS, E ;
HANSEN, CB ;
KAO, GY ;
ZALIPSKY, S .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1995, 1237 (02) :99-108
[6]   Immunoliposome-mediated targeting of anti-cancer drugs in vivo [J].
Allen, TM ;
Ahmad, I ;
deMenezes, DEL ;
Moase, EH .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1995, 23 (04) :1073-1079
[7]   IMMUNE CLEARANCE OF LIPOSOMES INHIBITED BY AN ANTI-FC RECEPTOR ANTIBODY INVIVO [J].
ARAGNOL, D ;
LESERMAN, LD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (08) :2699-2703
[8]   Molecular vehicles for targeted drug delivery [J].
Backer, MV ;
Aloise, R ;
Przekop, K ;
Stoletov, K ;
Backer, JM .
BIOCONJUGATE CHEMISTRY, 2002, 13 (03) :462-467
[9]   Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries [J].
Barry, MA ;
Dower, WJ ;
Johnston, SA .
NATURE MEDICINE, 1996, 2 (03) :299-305
[10]   Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer [J].
Batist, G ;
Ramakrishnan, G ;
Rao, CS ;
Chandrasekharan, A ;
Gutheil, J ;
Guthrie, T ;
Shah, P ;
Khojasteh, A ;
Nair, MK ;
Hoelzer, K ;
Tkaczuk, K ;
Park, YC ;
Lee, LW .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1444-1454